SG11202012784SA - Ask1 inhibiting agents - Google Patents

Ask1 inhibiting agents

Info

Publication number
SG11202012784SA
SG11202012784SA SG11202012784SA SG11202012784SA SG11202012784SA SG 11202012784S A SG11202012784S A SG 11202012784SA SG 11202012784S A SG11202012784S A SG 11202012784SA SG 11202012784S A SG11202012784S A SG 11202012784SA SG 11202012784S A SG11202012784S A SG 11202012784SA
Authority
SG
Singapore
Prior art keywords
inhibiting agents
ask1
ask1 inhibiting
agents
inhibiting
Prior art date
Application number
SG11202012784SA
Other languages
English (en)
Inventor
Lopez De Turiso Felix Gonzalez
Michael Dechantsreiter
Zhili Xin
John Jones
Martin Himmelbauer
Original Assignee
Biogen Ma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biogen Ma Inc filed Critical Biogen Ma Inc
Publication of SG11202012784SA publication Critical patent/SG11202012784SA/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Neurosurgery (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Hospice & Palliative Care (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Psychiatry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
SG11202012784SA 2018-06-27 2019-06-26 Ask1 inhibiting agents SG11202012784SA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862690674P 2018-06-27 2018-06-27
PCT/US2019/039156 WO2020006031A1 (fr) 2018-06-27 2019-06-26 Agents inhibiteurs d'ask1

Publications (1)

Publication Number Publication Date
SG11202012784SA true SG11202012784SA (en) 2021-01-28

Family

ID=67254023

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11202012784SA SG11202012784SA (en) 2018-06-27 2019-06-26 Ask1 inhibiting agents

Country Status (22)

Country Link
US (2) US11814362B2 (fr)
EP (1) EP3814333A1 (fr)
JP (1) JP2021528456A (fr)
KR (1) KR20210024532A (fr)
CN (1) CN112638896A (fr)
AR (1) AR115636A1 (fr)
AU (1) AU2019291806A1 (fr)
BR (1) BR112020026423A2 (fr)
CA (1) CA3104662A1 (fr)
CL (1) CL2020003375A1 (fr)
CO (1) CO2021000782A2 (fr)
CR (1) CR20210049A (fr)
EA (1) EA202190034A1 (fr)
IL (1) IL279709A (fr)
JO (1) JOP20200318A1 (fr)
MA (1) MA53009A (fr)
MX (1) MX2020013895A (fr)
PE (1) PE20211379A1 (fr)
SG (1) SG11202012784SA (fr)
TW (1) TW202035389A (fr)
UY (1) UY38278A (fr)
WO (1) WO2020006031A1 (fr)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10669272B2 (en) 2018-06-27 2020-06-02 Bristol-Myers Squibb Company Substituted naphthyridinone compounds useful as T cell activators

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4938949A (en) 1988-09-12 1990-07-03 University Of New York Treatment of damaged bone marrow and dosage units therefor
TWI598347B (zh) * 2009-07-13 2017-09-11 基利科學股份有限公司 調節細胞凋亡信號之激酶的抑制劑
UY35212A (es) * 2012-12-21 2014-06-30 Gilead Sciences Inc Inhibidores de la quinasa que regula la señal de la apoptosis
MX2016008254A (es) * 2013-12-20 2016-10-14 Gilead Sciences Inc Inhibidores de cinasa reguladora de la señal de apoptosis.
WO2018151830A1 (fr) 2017-02-17 2018-08-23 Fronthera U.S. Pharmaceuticals Llc Inhibiteurs de kinase de régulation du signal apoptotique à base de pyridinyle

Also Published As

Publication number Publication date
PE20211379A1 (es) 2021-07-27
MA53009A (fr) 2021-05-05
CO2021000782A2 (es) 2021-01-29
EA202190034A1 (ru) 2021-04-08
US20210115020A1 (en) 2021-04-22
TW202035389A (zh) 2020-10-01
WO2020006031A1 (fr) 2020-01-02
AU2019291806A1 (en) 2021-01-07
US20240109867A1 (en) 2024-04-04
IL279709A (en) 2021-03-01
CA3104662A1 (fr) 2020-01-02
EP3814333A1 (fr) 2021-05-05
MX2020013895A (es) 2021-07-21
UY38278A (es) 2020-01-31
US11814362B2 (en) 2023-11-14
AR115636A1 (es) 2021-02-10
KR20210024532A (ko) 2021-03-05
CL2020003375A1 (es) 2021-09-03
WO2020006031A8 (fr) 2020-09-24
JOP20200318A1 (ar) 2020-12-10
JP2021528456A (ja) 2021-10-21
CN112638896A (zh) 2021-04-09
BR112020026423A2 (pt) 2021-03-23
CR20210049A (es) 2021-07-01

Similar Documents

Publication Publication Date Title
CA187856S (en) Caddy
IL269711A (en) ASK1 inhibitory compounds and their uses
GB201805174D0 (en) Compounds
GB201810092D0 (en) Compounds
GB201801355D0 (en) Compounds
GB201814169D0 (en) Blockchain autonoumous agents
GB201807924D0 (en) Compounds
GB201810581D0 (en) Compounds
GB201808093D0 (en) Compounds
GB201814151D0 (en) Compounds
GB201809102D0 (en) Compounds
IL279709A (en) ASK1 inhibitory agents
GB201817083D0 (en) Compounds
GB201812382D0 (en) Compounds
GB201810071D0 (en) Compounds
GB201803340D0 (en) Compounds
GB201814167D0 (en) Compounds
GB201801128D0 (en) Compounds
GB201801130D0 (en) Compounds
CA189391S (en) Padlock
ZA202103582B (en) Dna-cutting agent
ZA202103578B (en) Dna-cutting agent
GB201811826D0 (en) CAERvest 1
GB201818410D0 (en) Compounds
GB201817342D0 (en) Compounds